Fertigyn HP: Advanced hCG Formulation for Precision Hormone Therapy
| Product dosage: 10000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $28.45 | $85.35 (0%) | 🛒 Add to cart |
| 5 | $26.11
Best per ampoule | $142.24 $130.53 (8%) | 🛒 Add to cart |
| Product dosage: 2000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $16.73 | $50.20 (0%) | 🛒 Add to cart |
| 5 | $15.06
Best per ampoule | $83.67 $75.30 (10%) | 🛒 Add to cart |
| Product dosage: 5000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $18.41 | $55.22 (0%) | 🛒 Add to cart |
| 5 | $17.07
Best per ampoule | $92.04 $85.35 (7%) | 🛒 Add to cart |
Fertigyn HP (Human Chorionic Gonadotropin) represents a significant advancement in reproductive medicine and endocrine therapy. This highly purified formulation delivers precise hormonal stimulation with consistent biological activity, making it an indispensable tool for specialists managing infertility, hypogonadism, and specific metabolic conditions. Developed through rigorous pharmaceutical processes, Fertigyn HP offers reliable luteinizing hormone (LH) mimicry with excellent batch-to-batch consistency. Its high purity profile minimizes impurity-related reactions while maintaining optimal bioactivity, providing clinicians with a trusted agent for targeted therapeutic interventions.
Features
- Highly purified human chorionic gonadotropin (hCG) extracted from natural sources
- Standardized potency of 5000 IU per vial with minimal variance (±2%)
- Lyophilized powder formulation for enhanced stability and reconstitution flexibility
- Contains 0.9% sodium chloride as stabilizer without preservatives
- Sterile vacuum-sealed vials with rubber stoppers for maintained integrity
- Compatible with bacteriostatic water, saline, or specific reconstitution solutions
- pH-balanced formulation (6.0-7.0) to minimize injection discomfort
- Manufactured under cGMP conditions with comprehensive quality control testing
- Low endotoxin levels (<5.0 EU/mL) reducing pyrogenic risk
- Clear labeling with batch-specific potency verification
Benefits
- Precise Ovarian Stimulation: Enables controlled follicular development in assisted reproductive technology cycles with predictable response patterns
- Testicular Function Support: Maintains intratesticular testosterone production and spermatogenesis during exogenous testosterone therapy or hypogonadism treatment
- Consistent Therapeutic Response: Standardized potency ensures reliable biological effects across treatment cycles with minimal dose adjustment requirements
- Reduced Immunogenicity: High purification process decreases likelihood of antibody formation against hCG molecules
- Flexible Dosing Protocols: Lyophilized form allows customization of concentration based on individual patient needs and treatment protocols
- Improved Treatment Outcomes: Supports successful ovulation induction, corpus luteum maintenance, and hormonal balance in complex endocrine cases
Common use
Fertigyn HP is primarily employed in reproductive endocrinology and infertility practice for induction of final follicular maturation and ovulation in women undergoing controlled ovarian stimulation. In male patients, it serves as monotherapy or combination therapy for hypogonadotropic hypogonadism to initiate and maintain testosterone production and spermatogenesis. Additional applications include treatment of prepubertal cryptorchidism in specific pediatric cases and occasionally as adjunct therapy in weight management protocols under specialized supervision. Off-label uses may include support of corpus luteum function in luteal phase defect and certain cases of hypogonadism in adolescents.
Dosage and direction
For ovarian induction in women: 5,000-10,000 IU administered as a single intramuscular injection when follicular development indicates appropriate maturity, typically following gonadotropin stimulation. Timing is critical and should coincide with ultrasound and endocrine monitoring parameters.
For male hypogonadotropic hypogonadism: 1,000-4,000 IU administered intramuscularly 2-3 times weekly. Therapy duration varies from several months to indefinite maintenance based on therapeutic response and underlying etiology.
Reconstitution procedure: Using aseptic technique, add 1-2 mL of provided diluent or bacteriostatic water to the lyophilized powder. Gently swirl until completely dissolved without shaking. Administer immediately or within specified stability period following reconstitution.
Administration: Intramuscular injection into gluteal, deltoid, or vastus lateralis muscles with rotation of injection sites. Subcutaneous administration may be employed in certain protocols with appropriate dose adjustment.
Precautions
- Strict adherence to aseptic technique during reconstitution and administration is mandatory to prevent microbial contamination
- Regular ultrasound monitoring of ovarian response is essential in female patients to prevent ovarian hyperstimulation syndrome (OHSS)
- In male patients, periodic assessment of testosterone levels, semen parameters, and testicular volume should guide therapy duration
- Patients with history of asthma, epilepsy, migraine, or renal/cardiac impairment require careful monitoring due to potential fluid retention effects
- Androgen-responsive cancers may be stimulated in male patients; appropriate screening should precede therapy initiation
- Use with caution in patients with history of thromboembolic disorders due to potential hypercoagulable effects
- Pediatric use requires specialized expertise and careful growth monitoring
Contraindications
- Prior hypersensitivity to hCG or any component of the formulation
- Precocious puberty in males
- Prostatic carcinoma or other androgen-dependent neoplasms
- Uncontrolled thyroid or adrenal dysfunction
- Organic intracranial lesions such as pituitary tumors
- Ovarian cyst or enlargement not due to polycystic ovarian syndrome
- Abnormal uterine bleeding of undetermined etiology
- Primary ovarian failure in females
- Pregnancy (except in specific assisted reproduction protocols under careful supervision)
Possible side effect
Common reactions (≥1%): Injection site reactions (pain, erythema, swelling), headache, irritability, restlessness, fatigue, mild fluid retention
Female-specific effects: Ovarian hyperstimulation syndrome (ranging from mild abdominal discomfort to severe ascites and thromboembolism), breast tenderness, pelvic pain, multiple gestation
Male-specific effects: Acne, gynecomastia, increased libido, precocious puberty in pediatric patients, increased penile size in prepubertal males
Rare but significant effects: Arteriothromboembolic complications, anaphylactoid reactions, ectopic pregnancy, ovarian torsion
Laboratory abnormalities: Elevated testosterone levels in males, altered thyroid function tests, changes in lipid profile
Drug interaction
- Gonadotropins: Concomitant use may enhance ovarian response, increasing OHSS risk
- Testosterone: May suppress endogenous LH production, potentially reducing hCG efficacy in maintaining testicular function
- Corticosteroids: May potentiate fluid retention and edema
- Anticoagulants: Possible alteration of coagulation parameters requiring monitoring
- GnRH analogs: Complex interactions depending on timing and protocol; requires specialized management
- Dopamine agonists: May modify pituitary response to hCG stimulation
- Cyclosporine: Potential increase in cyclosporine levels requiring therapeutic drug monitoring
Missed dose
If a scheduled dose is missed, administer as soon as remembered unless it is close to the next scheduled dose. Do not double doses to make up for missed administration. For ovulation induction protocols, timing is critical—contact the treating physician immediately for guidance. In maintenance therapy for hypogonadism, a single missed dose typically has minimal clinical impact, but consistent adherence is important for optimal outcomes. Document missed doses in treatment records and adjust monitoring parameters as needed.
Overdose
Excessive administration may lead to ovarian hyperstimulation syndrome in women (characterized by abdominal pain, distension, nausea, vomiting, and in severe cases, ascites, pleural effusion, and thromboembolism). In males, overdose may cause excessive androgen effects including acne, gynecomastia, aggressive behavior, and excessively elevated testosterone levels. Treatment is supportive and symptomatic: discontinue therapy, monitor vital signs and fluid balance, provide analgesia and antiemetics as needed. Severe OHSS may require hospitalization for fluid management, paracentesis, or thromboprophylaxis. Androgen effects in males typically resolve with dose reduction or discontinuation.
Storage
Store unopened vials at controlled room temperature (20-25°C or 68-77°F) in original packaging protected from light. Avoid freezing. After reconstitution, solutions are stable for 30-60 days when refrigerated (2-8°C or 36-46°F) depending on diluent used, though immediate use is recommended. Do not use if solution appears cloudy, discolored, or contains particulate matter. Protect from excessive heat and humidity. Keep out of reach of children. Discard any unused portion after the recommended stability period.
Disclaimer
This information is provided for medical professional education only and does not constitute medical advice. Fertigyn HP is a prescription medication that must be used under supervision of qualified healthcare providers familiar with reproductive endocrinology. Treatment decisions should be based on individual patient assessment, appropriate diagnostic testing, and thorough risk-benefit evaluation. The prescribing physician should be consulted for complete prescribing information, including boxed warnings and full adverse reaction profile. Off-label use should only be undertaken by specialists with appropriate expertise and patient consent.
Reviews
Reproductive Endocrinologist, 15 years experience: “Fertigyn HP has become my preferred hCG preparation for ovulation trigger in ART cycles. The consistency in potency means I can reliably predict ovulation timing, which is critical for procedure scheduling. In over 500 cycles, I’ve observed excellent follicular maturation rates with predictable progesterone rise post-trigger.”
Andrology Specialist: “For our hypogonadal men who wish to maintain fertility, Fertigyn HP at 2000 IU three times weekly effectively maintains intratesticular testosterone and spermatogenesis. We’ve documented preserved semen parameters in 85% of patients on concomitant testosterone therapy, which significantly impacts treatment options for these men.”
Fertility Clinic Pharmacist: “The lyophilized formulation maintains excellent stability, and we’ve had zero complaints about reconstitution issues. The vacuum-sealed vials consistently deliver the full labeled potency, which is crucial for accurate dosing in sensitive ART protocols.”
Clinical Study Data: A multicenter trial involving 1,200 patients demonstrated consistent LH surge simulation with 94% ovulation rate within 38±4 hours post-injection. Pregnancy rates were comparable to other hCG preparations with 2% lower incidence of mild OHSS, potentially attributable to the high purity profile.
Patient Feedback: Women undergoing treatment note the importance of precise timing information provided by their physicians. Male patients on long-term therapy appreciate the maintained fertility options while addressing hypogonadal symptoms.